Compare Novo Nordisk A/S (NVO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oatly Group AB - ADR — how do they compare? Novo Nordisk A/S trades at $46.52 (market cap $207.85B), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Novo Nordisk A/S is far larger — about 499.7× Oatly Group AB - ADR's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| NVO | OTLY | |
|---|---|---|
Market Cap | $207.85B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $18.54 |
52-Week Low | $35.29 | $8.03 |
Enterprise Value | $222.55B | $920.39M |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Oatly (OTLY) trades at $13.23, up 0.84% today, with a bullish technical signal supported by moving averages and RSI. The company reported Q2 2026 revenue of $240.1 million, beating expectations, and raised its full-year outlook. However, it remains unprofitable with a net income margin of -13.81% and negative cash flow. Analyst sentiment is mixed with 44% buy ratings, 50% hold, and 6% sell.
Outlook hinges on revenue growth and margin improvements, but risks include high debt, persistent cash burn, and delayed profitability. The stock offers speculative upside if operational turnaround accelerates, yet investors face significant financial stability concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
